Biopharma
Canaan Partners Raises Additional $100M for Biotech Investments, Adds Pfizer Vet Uwe Schoenbeck
Canaan Partners, Biotech investments, Venture capital, Pfizer, Uwe Schoenbeck, Biopharma, Healthcare, Venture partner
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Biopharma Layoff Tracker 2024: Merck, Rapt, Aslan and More Cut Staff
Biopharma, Layoffs, Merck, Rapt, Aslan, Pharmaceutical Industry, Job Cuts, Restructuring
Pfizer Faces Key R&D Challenges as Chief Scientific Officer Mikael Dolsten Departs
Pfizer, Mikael Dolsten, Chief Scientific Officer, R&D Challenges, Biopharma Industry
Biopharma Layoff Tracker 2024: CureVac, Takeda, Aerovate and More Cut Staff
Biopharma, Layoffs, 2024, CureVac, Takeda, Aerovate, Job Cuts, Industry Trends
Amylyx Acquires GLP-1 Receptor Antagonist for $35M to Fill Pipeline Gap
Amylyx Pharmaceuticals, Relyvrio, GLP-1 receptor antagonist, Eiger Biopharma, pipeline expansion, ALS, Wolfram syndrome
Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC
Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion
Western In-Licensing Deals with Chinese Companies: Focus on Disease Areas and Drug Types
, In-licensing deals, Chinese pharmaceutical companies, Western pharmaceutical companies, Disease areas, Drug types, Cross-border partnerships, Biopharma, Licensing trends,
Biopharma Funding Levels Reach ‘New Normal’ Until Federal Interest Rates Change: PitchBook
Biopharma, Funding Levels, Federal Interest Rates, PitchBook, Venture Capital
Lilly Initiates Search for New CFO Following Anat Ashkenazi’s Departure to Alphabet
Anat Ashkenazi, CFO, Eli Lilly, Alphabet, Google, Ruth Porat, Sundar Pichai, Financial Leadership, Biopharma, Tech Industry